The impact of pulmonary hypertension on outcomes of transcatheter mitral valve replacement in mitral annular calcification. Issue 5 (12th January 2022)

• Record Type: Journal Article
• Authors: Cajigas, Hector R.; Kaptzan, Tatiana; Lewis, Bradley; El‐Sabbagh, Abdallah; Al‐Hijji, Mohammed; Eleid, Mackram; Alkhouli, Mohamad; Wang, Dee Dee; Eng, Marvin; Kodali, Susheel; George, Isaac; Chakravarty, Tarun; Pershad, Ashish; O'Hair, Daniel; Jones, Noah; Makkar, Raj; Reisman, Mark; Leon, Martin; O'Neill, William; Rihal, Charanjit; Guerrero, Mayra
• Is Part Of: Catheterization and cardiovascular interventions. Volume 99:Issue 5(2022)
• Page Start: 1647
• Page End: 1658
• Publication Date: 2022-01-12
• Subjects: mitral annular calcification -- pulmonary hypertension -- transcatheter mitral valve replacement; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.30057
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: To assess the impact of pulmonary hypertension (PH) on outcomes of patients with severe mitral annular calcification (MAC) undergoing transcatheter mitral valve replacement (TMVR). Background: PH is associated with poor outcomes after mitral valve surgery. Whether the presence of PH in patients with MAC undergoing (TMVR) is associated with poor outcomes, is unknown. Methods: Retrospective evaluation of 116 patients from 51 centers in 11 countries who underwent TMVR with valve in mitral annular calcification (ViMAC) using balloon‐expandable aortic transcatheter valves (THVs) from September 2012 to March 2017. Pulmonary artery systolic blood pressure (PASP) by echocardiogram was available in 90 patients. The subjects were stratified based on PASP: No PH = PASP ≤35 mmHg ( n = 11); mild to moderate PH = PASP 36–49 mmHg ( n = 21) and severe PH = PASP ≥50 mmHg (n = 58). Clinical, procedural, and echocardiographic outcomes were assessed. Results: Mean age was 72.7 (±12.8) years, 59 (65.6%) were female, Society of Thoracic Surgeons score was 15.8 + 11.8% and 90.0% where in New York Heart Association (NYHA) class III–IV. There was no significant difference in all‐cause mortality at 30 days (no PH = 27.3%, mild–moderate PH = 19.0%, severe PH = 31.6%; p = 0.55) or at 1 year (no PH = 54.5%, mild–moderate PH = 38.1%, severe PH = 56.1%; p = 0.36). No difference in adverse events, NYHA class or amount of residual mitral regurgitation at 1 year were observed between the groups. Conclusion: This study suggests that the presence of PH in patients with predominantly mitral stenosis with MAC undergoing TMVR does not impact mortality or adverse events. Further studies are needed to fully understand the effect of PH in this group of patients.